AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results